The long, complex battle over who owns the rights to the Kraft peanut butter trade dress just promised to get longer, with Kraft winning approval to bring fresh allegations against Bega mid-trial.
Global pharmaceutical giant Sanofi-Aventis has launched patent infringement proceedings against generic drug maker Alphapharm seeking “urgent interlocutory relief” to prevent a generic injector pen from being listed on the market.
Plastic banknote company Securency has been ordered to pay more than $64 million after it tricked its agent in Nigeria into signing away his commission in what the Federal Court called a “shabby fraud”.
Fundraising company Appco Group Australia has failed in its bid to put a massive sham contracting class action in the Federal Court on hold while it fights a ruling that let the case continue as a representative proceeding.
The two coal companies at the centre of an ACCC case alleging an unlawful agreement to rig the tender process for mining exploration licenses were not competitors, a judge has ruled in dismissing the watchdog’s cartel case.
A Federal Court judge skipped vital witness testimony when he ruled Reckitt Benckiser misled consumers about the effectiveness of its Nurofen painkiller, the pharmaceutical company told the Full Federal Court Monday.
Viterra is blaming several former employees for representations made about malt quality in the lead-up to the $420 million sale of its Joe White business to Cargill Australia in 2013.
Milk supplier Murray Goulburn has been hit with a second class action over its profit forecast revision in 2016 that wiped 40 percent off the dairy cooperative’s investment value.
Building products maker Caesarstone can register two trade marks despite their deceptive similarity to a mark by ceramic tile maker Ceramiche Caesar, a judge has ruled, after finding Caesarstone had shown honest concurrent use of the marks.
Reckitt Benckiser will try to convince the Full Federal Court on Monday that a judge got it wrong when he found it misled consumers with claims that Nurofen is a more effective pain killer than rival GlaxoSmithKline’s Panadol.